- Home
- AFJK vs MCRB Comparison
AFJK vs MCRB Comparison
Compare AFJK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFJK
- MCRB
- Stock Information
- Founded
- AFJK 2023
- MCRB 2010
- Country
- AFJK United States
- MCRB United States
- Employees
- AFJK N/A
- MCRB N/A
- Industry
- AFJK
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- AFJK
- MCRB Health Care
- Exchange
- AFJK NYSE
- MCRB Nasdaq
- Market Cap
- AFJK 68.6M
- MCRB 72.0M
- IPO Year
- AFJK 2023
- MCRB 2015
- Fundamental
- Price
- AFJK $11.14
- MCRB $7.05
- Analyst Decision
- AFJK
- MCRB Hold
- Analyst Count
- AFJK 0
- MCRB 5
- Target Price
- AFJK N/A
- MCRB $73.67
- AVG Volume (30 Days)
- AFJK 14.9K
- MCRB 93.5K
- Earning Date
- AFJK 01-01-0001
- MCRB 05-07-2025
- Dividend Yield
- AFJK N/A
- MCRB N/A
- EPS Growth
- AFJK N/A
- MCRB N/A
- EPS
- AFJK N/A
- MCRB 8.98
- Revenue
- AFJK N/A
- MCRB N/A
- Revenue This Year
- AFJK N/A
- MCRB N/A
- Revenue Next Year
- AFJK N/A
- MCRB N/A
- P/E Ratio
- AFJK $45.11
- MCRB $0.84
- Revenue Growth
- AFJK N/A
- MCRB N/A
- 52 Week Low
- AFJK $10.24
- MCRB $6.53
- 52 Week High
- AFJK $11.20
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- AFJK N/A
- MCRB 38.95
- Support Level
- AFJK N/A
- MCRB $7.32
- Resistance Level
- AFJK N/A
- MCRB $7.86
- Average True Range (ATR)
- AFJK 0.00
- MCRB 0.63
- MACD
- AFJK 0.00
- MCRB 0.10
- Stochastic Oscillator
- AFJK 0.00
- MCRB 28.89
About AFJK AIMEI HEALTH TECHNOLOGY CO LTD
Aimei Health Technology Co Ltd is a blank check company.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.